10:38 AM EDT, 06/04/2024 (MT Newswires) -- Silo Pharma ( SILO ) said Tuesday it submitted a pre-investigational new drug briefing package and meeting request to the US Food and Drug Administration for its SPC-15 treatment for post-traumatic stress disorder and stress-induced anxiety disorder.

The treatment has additive benefits for fighting stress-induced pathophysiology, both at the behavioral and neural levels, the company said, citing pre-clinical data.

The SPC-15 program's next steps include a progressive intellectual and neurological deterioration study followed by a GLP study, both scheduled to begin in the second half of 2024, Silo Pharma ( SILO ) said.

The company's shares were up more than 5% in recent trading.

Price: 2.15, Change: +0.12, Percent Change: +5.76